ArticleMedicine2026
Relationship between klotho and psoriasis: A cross-sectional analysis of NHANES 2009-2010 and Mendelian randomization study.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis commonly presents with systemic comorbidities as a chronic, immune-mediated condition. The antiaging protein klotho, recognized for its dual anti-inflammatory and antioxidant properties, may modulate psoriasis pathogenesis, although human data are currently scarce. This cross-sectional analysis enrolled 1407 participants, including 50 with psoriasis. Serum klotho was log10-transformed, and multivariable logistic regression was used to assess its association with psoriasis. Restricted cubic spline analysis was performed to evaluate potential nonlinearity. Kaplan-Meier curves were used as unadjusted descriptive survival analyses, and Cox proportional hazards models were fitted among participants with psoriasis. Causal relationships were further assessed using Mendelian randomization. Lower serum klotho levels were independently associated with a higher prevalence of psoriasis after full adjustment (odds ratio = 0.11, 95% confidence interval: 0.02-0.80, P = .029). Restricted cubic spline analysis suggested a borderline overall association (P for overall = .055) without significant evidence of nonlinearity (P for nonlinearity = .344). Among participants with psoriasis, low klotho defined using the optimal cutoff of 2.92 was associated with poorer survival in unadjusted Kaplan-Meier analysis (P = .031), and higher log10-transformed klotho was associated with a lower risk of all-cause mortality in the fully adjusted Cox model. Mendelian randomization found no evidence of a causal association between genetically predicted klotho and psoriasis but suggested a potential protective effect against arthritis. Reduced serum klotho levels are associated with psoriasis prevalence, metabolic comorbidities, and mortality among participants with psoriasis. Klotho may represent a candidate biomarker related to inflammatory and cardiometabolic risk in psoriasis; however, causal and prognostic implications require validation in prospective cohorts and mechanistic studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.